Imiquimod-Induced Psoriasis Efficacy Studies

Imiquimod (IMQ) is a toll-like receptor agonist that acts as an immune response modifier. Topical application of IMQ to the skin of susceptible BALB/cJ and C57BL/6J mice induces inflammation with features commonly found in human psoriatic skin, including erythema and scaling. The advantage of this model over other inducible psoriasis models is the fast induction of clinical phenotypes for rapid therapeutic screening.

Standard psoriasis study designs

• 6-8 week old female BALB/cJ
• Scaling & Lesion Scores and Erythema Scores measure daily
• Histopathological evaluation of the skin

Representative Data